このページの翻訳は実験的なもので、現在開発中です。お待ちしております
TG Therapeutics マネジメント
マネジメント 基準チェック /34
TG Therapeutics'の CEO はMike Weissで、 Dec2011年に任命され、 の在任期間は 12.67年です。 の年間総報酬は$ 15.84Mで、 5.5%給与と94.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の5.72%を直接所有しており、その価値は$ 206.58M 。経営陣と取締役会の平均在任期間はそれぞれ12.7年と10.7年です。
主要情報
Mike Weiss
最高経営責任者
US$15.8m
報酬総額
| CEO給与比率 | 5.5% |
| CEO在任期間 | 12.8yrs |
| CEOの所有権 | 5.7% |
| 経営陣の平均在職期間 | 12.8yrs |
| 取締役会の平均在任期間 | 10.8yrs |
経営陣の近況
Recent updates
TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry
Sep 01
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$96m |
| Mar 31 2024 | n/a | n/a | US$41m |
| Dec 31 2023 | US$16m | US$875k | US$13m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$176m |
| Mar 31 2023 | n/a | n/a | -US$169m |
| Dec 31 2022 | US$10m | US$875k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$239m |
| Jun 30 2022 | n/a | n/a | -US$288m |
| Mar 31 2022 | n/a | n/a | -US$326m |
| Dec 31 2021 | US$43m | US$1m | -US$348m |
| Sep 30 2021 | n/a | n/a | -US$343m |
| Jun 30 2021 | n/a | n/a | -US$345m |
| Mar 31 2021 | n/a | n/a | -US$319m |
| Dec 31 2020 | US$32m | US$1m | -US$279m |
| Sep 30 2020 | n/a | n/a | -US$231m |
| Jun 30 2020 | n/a | n/a | -US$206m |
| Mar 31 2020 | n/a | n/a | -US$189m |
| Dec 31 2019 | US$13m | US$637k | -US$173m |
| Sep 30 2019 | n/a | n/a | -US$187m |
| Jun 30 2019 | n/a | n/a | -US$159m |
| Mar 31 2019 | n/a | n/a | -US$167m |
| Dec 31 2018 | US$14m | US$656k | -US$173m |
| Sep 30 2018 | n/a | n/a | -US$150m |
| Jun 30 2018 | n/a | n/a | -US$148m |
| Mar 31 2018 | n/a | n/a | -US$132m |
| Dec 31 2017 | US$10m | US$525k | -US$118m |
報酬と市場: Mikeの 総報酬 ($USD 15.84M ) は、 US市場 ($USD 6.76M ) の同規模の企業の平均を上回っています。
報酬と収益: Mikeの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Mike Weiss (58 yo)
12.8yrs
在職期間
US$15,837,559
報酬
Mr. Michael S. Weiss, Esq. J.D. also known as Mike, serves as Director of Urica Therapeutics, Inc. He has been an Executive Chairman of Mustang Bio, Inc. since January 2017 and served as its Interim Presid...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman | 12.8yrs | US$15.84m | 5.72% $ 195.4m | |
| CFO, Corporate Secretary & Treasurer | 12.8yrs | US$1.87m | 0.48% $ 16.3m | |
| Senior Vice President of Corporate Communications | no data | データなし | データなし | |
| Chief Commercialization Officer | 6.3yrs | データなし | データなし |
12.8yrs
平均在職期間
経験豊富な経営陣: TGTXの経営陣は経験豊富で経験豊富です（平均在職期間は12.7年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman | 12.8yrs | US$15.84m | 5.72% $ 195.4m | |
| Lead Independent Director | 12.4yrs | US$304.70k | 0.17% $ 5.7m | |
| Independent Director | 9.8yrs | US$264.70k | 0.18% $ 6.3m | |
| Independent Director | 11.8yrs | US$262.20k | 0.17% $ 5.8m | |
| Independent Director | 4.4yrs | US$259.70k | 0.073% $ 2.5m | |
| Independent Director | 9.3yrs | US$262.20k | 0.17% $ 5.7m |
10.8yrs
平均在職期間
58.5yo
平均年齢
経験豊富なボード: TGTXの 取締役会 は経験豊富で 経験豊富 です ( 10.7年の平均在任期間)。